X

Trial Profile

Safety and efficacy of Belimumab After B cell depletion therapy in systemic LUPUS erythematosus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Dec 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary)
Indications Systemic lupus erythematosus
Focus Therapeutic Use
Acronyms BEAT LUPUS

Most Recent Events

14 Nov 2022 Results assessing to identify biomarkers of response to belimumab after rituximab to aid a personalised approach to therapy, presented at the ACR Convergence 2022.
04 Jun 2022 Data from this study used to identify biomarkers of clinical response to belimumab after rituximab presented at the 23rd Annual Congress of the European League Against Rheumatism
26 Oct 2021 Results published in the Annals of Internal Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com